JPH09301879A - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
JPH09301879A
JPH09301879A JP8118860A JP11886096A JPH09301879A JP H09301879 A JPH09301879 A JP H09301879A JP 8118860 A JP8118860 A JP 8118860A JP 11886096 A JP11886096 A JP 11886096A JP H09301879 A JPH09301879 A JP H09301879A
Authority
JP
Japan
Prior art keywords
antacid
sofalcone
pharmaceutical composition
day
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP8118860A
Other languages
Japanese (ja)
Other versions
JP4726268B2 (en
Inventor
Norihiko Ikegami
敬彦 池上
Shigeru Takakura
卯 高椋
Toru Nishikawa
徹 西川
Yoshinobu Tsunenari
嘉伸 恒成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP11886096A priority Critical patent/JP4726268B2/en
Publication of JPH09301879A publication Critical patent/JPH09301879A/en
Application granted granted Critical
Publication of JP4726268B2 publication Critical patent/JP4726268B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition containing sofalcone and effective for shortening the treatment period of various diseases. SOLUTION: This composition contains sofalcone, scopolia extract and an antacid. The amount of the scopolia extract is 0.01-5 pts.wt. in terms of dry component based on 1 pt.wt. of sofalcone and that of the antacid is selected to keep the pH in the stomach to 3-5. In the case of using sodium bicarbonate and magnesium silicate aluminate as the antacid, the amounts of the components are 50-2,000mg of sodium bicarbonate and 50-1,500mg of magnesium silicate aluminate per dose in the case of administering the agent at a rate of 3 doses a day. The pharmaceutical composition can be administered orally or parenterally in one to several doses a day for adult for the treatment of gastritis. The administration rate of sofalcone is preferably 10-1,000mg/day. It is preferable from the viewpoint of the treating effect on gastritis to use an agent having quick-acting gastric acid neutralizing action in combination with an agent having sustained gastric acid neutralizing action as the antacid.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、医薬組成物に関す
る。
TECHNICAL FIELD The present invention relates to a pharmaceutical composition.

【0002】[0002]

【従来の技術】近年、社会生活におけるストレスの増加
や食事習慣の変化などにより、胃炎、胃潰瘍などの上部
消化管疾患の患者が増加している。その治療剤として種
々の薬剤が開発されており、代表的なものとしてソファ
ルコンをあげることができる。ソファルコンは広豆根の
研究から開発されたイソプレニルカルコン誘導体であ
り、化学名は2’−カルボキシメトキシ−4,4’−ビ
ス(3−メチル−2−ブテニルオキシ)カルコンと称
し、その配合製剤が特開平7−179346号公報、特
開平4−112824号公報などに記載されている。し
かしながら、従来知られているソファルコン配合剤は疾
病の治療に対して必ずしも満足できるものではなかっ
た。
2. Description of the Related Art In recent years, the number of patients with upper gastrointestinal tract diseases such as gastritis and gastric ulcer has been increasing due to an increase in stress in social life and changes in dietary habits. Various drugs have been developed as the therapeutic agent, and a typical example thereof is sofa lucone. Sofalcon is an isoprenyl chalcone derivative developed from the study of broad roots, the chemical name is 2'-carboxymethoxy-4,4'-bis (3-methyl-2-butenyloxy) chalcone, and its combination preparation. Are described in JP-A-7-179346 and JP-A-4-112824. However, the conventionally known Sofalcone combination agents have not always been satisfactory for treating diseases.

【0003】[0003]

【発明が解決しようとする課題】本発明は、ソファルコ
ンを配合した製剤による、各種疾病の治療期間の短縮を
目的とする。
DISCLOSURE OF THE INVENTION The present invention aims to shorten the treatment period for various diseases by using a preparation containing sofa lucone.

【0004】[0004]

【課題を解決するための手段】本発明者らは上記事情を
鑑み種々検討した結果、ソファルコン、ロートエキスお
よび制酸剤を配合した医薬組成物が胃炎の治療期間を大
幅に短縮することを見いだし本発明を完成した。すなわ
ち本発明はソファルコン、ロートエキスおよび制酸剤か
らなる医薬組成物である。
Means for Solving the Problems As a result of various investigations in view of the above circumstances, the present inventors have found that a pharmaceutical composition containing sofa lucone, a funnel extract, and an antacid significantly shortens the period for treating gastritis. Found and completed the present invention. That is, the present invention is a pharmaceutical composition comprising sofa lucone, a funnel extract and an antacid.

【0005】[0005]

【発明の実施の形態】本発明においてロートエキスとは
ロートコンを常法により抽出したものもしくはその乾燥
物などである。制酸剤とは炭酸水素ナトリウム、ケイ酸
アルミン酸マグネシウム、リン酸水素カルシウム、メタ
ケイ酸アルミン酸ナトリウム、合成ヒドロタルサイトな
どをあげることができるが、好ましいものとして炭酸水
素ナトリウムおよびケイ酸アルミン酸マグネシウムをあ
げることができる。制酸剤は2種以上を用いてもよく、
特に速効的な胃酸中和作用を有する薬剤と持続的な胃酸
中和作用を有する薬剤を併用すると胃炎の治療効果の点
で好ましい。特に、炭酸水素ナトリウムおよびケイ酸ア
ルミン酸マグネシウムを同時配合すると胃炎治療効果の
点で最も好ましい。
BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, the roto extract is a product obtained by extracting rotocon by a conventional method or a dried product thereof. Examples of the antacid include sodium hydrogencarbonate, magnesium aluminate silicate, calcium hydrogenphosphate, sodium aluminometasilicate, synthetic hydrotalcite, and the like, with preference given to sodium hydrogencarbonate and magnesium aluminate silicate. Can be raised. Two or more antacids may be used,
In particular, it is preferable to use a drug having a fast-acting gastric acid-neutralizing action in combination with a drug having a persistent gastric-acid neutralizing action in terms of the therapeutic effect on gastritis. In particular, simultaneous blending of sodium hydrogen carbonate and magnesium aluminate silicate is most preferable from the viewpoint of therapeutic effect on gastritis.

【0006】各配合成分はソファルコン1重量部に対し
て、ロートエキスの乾燥物換算で0.01〜5重量部、
好ましくは0.05〜2重量部、最も好ましくは0.1
重量部である。また、制酸剤の量は、胃内のpHを3〜
5に保持するのに充分な量が好ましい。制酸剤として炭
酸水素ナトリウムおよびケイ酸アルミン酸マグネシウム
を用いた場合の配合量は、1日3回投与の場合、1回分
で炭酸水素ナトリウム50〜2000mg、好ましくは
100〜500mg、最も好ましくは200mgであ
り、ケイ酸アルミン酸マグネシウムは50〜1500m
g、好ましくは150〜500mg、最も好ましくは3
00mgである。
[0006] Each blending component is 0.01 to 5 parts by weight in terms of a dried product of the funnel extract, relative to 1 part by weight of Sofalcone
Preferably 0.05 to 2 parts by weight, most preferably 0.1.
Parts by weight. Also, the amount of antacid should be adjusted to pH in the stomach of 3 to
A sufficient amount to hold at 5 is preferred. When sodium hydrogen carbonate and magnesium aluminate silicate are used as antacids, the dosage is 50 to 2000 mg, preferably 100 to 500 mg, and most preferably 200 mg of sodium bicarbonate per administration when administered three times a day. And magnesium aluminate silicate is 50-1500 m
g, preferably 150-500 mg, most preferably 3
00 mg.

【0007】本発明の医薬組成物を胃炎の治療に用いた
場合、通常、成人に対して1日あたり1回〜数回に分け
て経口または非経口で投与することができる。ソファル
コンの投与量は10〜1000mg/日が好ましい。こ
の投与量は年齢、体重、病状などにより適宜増減するこ
とができる。
When the pharmaceutical composition of the present invention is used for treating gastritis, it can be usually orally or parenterally administered to an adult once to several times a day. The dose of sofalcon is preferably 10 to 1000 mg / day. This dose can be appropriately increased or decreased depending on the age, body weight, medical condition and the like.

【0008】本発明の医薬は、錠剤、顆粒剤、散剤、カ
プセル剤、液剤など経口投与形態または注射剤、塗布剤
などの非経口投与形態の通常の製剤として用いる。
The drug of the present invention is used as a usual preparation in an oral dosage form such as tablets, granules, powders, capsules, solutions or parenteral dosage forms such as injections and coatings.

【0009】これらの製剤は、常法により調製すること
ができる。製剤の調製に使用する担体としては、乳糖、
デンプン、砂糖、マンニトール、結晶セルロースなどの
賦形剤、ヒドロキシプロピルセルロース、ヒドロキシプ
ロピルメチルセルロース、ゼラチン、ポリビニルピロリ
ドンなどの結合剤、カルボキシメチルセルロースカルシ
ウム、低置換度ヒドロキシプロピルセルロースなどの崩
壊剤、ステアリン酸マグネシウム、硬化ヒマシ油、タル
クなどの滑択剤があり、この他必要に応じて溶解補助
剤、緩衝剤、保存剤、香料、色素、矯味剤などを使用す
ることができる。
These formulations can be prepared by a conventional method. Carriers used in the preparation of formulations include lactose,
Excipients such as starch, sugar, mannitol, crystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, gelatin, binders such as polyvinylpyrrolidone, carboxymethylcellulose calcium, disintegrating agents such as low-substituted hydroxypropylcellulose, magnesium stearate, There are lubricants such as hydrogenated castor oil and talc, and if necessary, solubilizing agents, buffers, preservatives, perfumes, dyes, flavoring agents and the like can be used.

【0010】[0010]

【実施例】以下に実施例および試験例により本発明をさ
らに詳細に説明する。
The present invention will be described in more detail with reference to the following examples and test examples.

【0011】実施例1 ソファルコン 300mg、ロートエキス3倍散 90
mg、炭酸水素ナトリウム 600mgおよびケイ酸ア
ルミン酸マグネシウム 900mgをとり、日本薬局方
製剤総則、散剤の項の製法に準じ調製し、3分包して散
剤を得た。
Example 1 Sofalcon 300 mg, funnel extract 3 times 90
mg, sodium hydrogencarbonate 600 mg and magnesium aluminate silicate 900 mg were prepared according to the manufacturing method of the Japanese Pharmacopoeia General Formulation, Powder Section, and packaged for 3 minutes to obtain a powder.

【0012】試験例 実施例1で調製した散剤を165名(男性75例、女性
90例、平均年齢47.1歳)の胃炎患者に1回1包、
1日3回経口投与して自覚症状(胃痛、胃部不快感、胃
重感、胃部膨満感、胃もたれ、はきけ、胸やけ、げっ
ぷ、胸のつかえ)の改善度を見た。総合改善度をソファ
ルコンのみの製剤についての文献(診療と新薬、第23
巻、2619−2631頁、1986年)に記載のデー
タと比較した。実施例、比較データともソファルコンの
含有量は1包あたり100mgで同一である。
Test Example The powder prepared in Example 1 was packaged once for 165 patients (75 men, 90 women, average age 47.1 years) with gastritis,
Oral administration was carried out three times a day, and the degree of improvement in subjective symptoms (stomach pain, stomach discomfort, stomach sensation, gastric bloating, stomach lean, brush, heartburn, belching, chest tightness) was observed. The total improvement is described in the literature on the preparation of Sofalcone only (medical care and new drugs, No. 23).
Vol. 2619-2631, 1986). The content of sofa lucone was the same in each of the Examples and Comparative Data, 100 mg per package.

【0013】結果 自覚症状の中等度以上の改善度は実施例1記載の散剤は
2週間投与で88.4%であった。文献記載データでは
4週間投与でも80.5%である。このことから本発明
の医薬組成物は従来技術と比較し、胃炎治療期間の短縮
を図っていることが明らかに解る。
Results The moderate or higher degree of improvement in subjective symptoms was 88.4% when the powder described in Example 1 was administered for 2 weeks. According to the data described in the literature, it is 80.5% even after administration for 4 weeks. From this, it is clear that the pharmaceutical composition of the present invention is intended to shorten the period for treating gastritis, as compared with the prior art.

【0014】[0014]

【発明の効果】上記試験例から明らかなように、本発明
によりソファルコンを投与した胃炎患者の治療期間を短
縮することが可能になった。また、ソファルコンが有効
なその他の疾病の治療期間を短縮することが可能になっ
た。
EFFECTS OF THE INVENTION As is clear from the above-mentioned test examples, the present invention makes it possible to shorten the treatment period of gastritis patients to whom sofarcone was administered. In addition, it has become possible to shorten the treatment period for other diseases for which Sofalucon is effective.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 //(A61K 31/19 35:78 33:06 33:00) (72)発明者 恒成 嘉伸 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification number Office reference number FI technical display location // (A61K 31/19 35:78 33:06 33:00) (72) Inventor Koshinari Yoshinobu 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 ソファルコン、ロートエキスおよび制酸
剤を配合することを特徴とする医薬組成物。
1. A pharmaceutical composition comprising sofalcon, a funnel extract and an antacid.
【請求項2】 上部消化管疾患治療剤である請求項1記
載の医薬組成物。
2. The pharmaceutical composition according to claim 1, which is a therapeutic agent for upper gastrointestinal tract diseases.
【請求項3】 制酸剤が、ケイ酸アルミン酸マグネシウ
ムおよび炭酸水素ナトリウムである請求項1または2に
記載の医薬組成物。
3. The pharmaceutical composition according to claim 1, wherein the antacid is magnesium aluminate silicate and sodium hydrogen carbonate.
JP11886096A 1996-05-14 1996-05-14 Pharmaceutical composition Expired - Lifetime JP4726268B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11886096A JP4726268B2 (en) 1996-05-14 1996-05-14 Pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11886096A JP4726268B2 (en) 1996-05-14 1996-05-14 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
JPH09301879A true JPH09301879A (en) 1997-11-25
JP4726268B2 JP4726268B2 (en) 2011-07-20

Family

ID=14746933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11886096A Expired - Lifetime JP4726268B2 (en) 1996-05-14 1996-05-14 Pharmaceutical composition

Country Status (1)

Country Link
JP (1) JP4726268B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102058552A (en) * 2010-12-22 2011-05-18 天津药物研究院药业有限责任公司 Sofalcone sustained release tablet and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102058552A (en) * 2010-12-22 2011-05-18 天津药物研究院药业有限责任公司 Sofalcone sustained release tablet and preparation method thereof

Also Published As

Publication number Publication date
JP4726268B2 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
US5156845A (en) Dry mouth lozenge
TW576743B (en) Extended release formulations of erythromycin derivatives
JP3977724B2 (en) Pharmaceutical composition
KR20000052950A (en) Chewing gum containing colloidal bismuth subcitrate
JPH07502527A (en) Compositions containing low doses of histamine-H2-receptor antagonists
US5661171A (en) Controlled release pilocarpine delivery system
JPS63313726A (en) Method and composition for treating nervous disease such as hemicrania by stimulating nervous cell
RU2762754C2 (en) Composition applicable in prevention and/or treatment of oral and gastrointestinal mucositis induced by oncological treatment
JPH08259445A (en) Medicinal composition for improving gastric emptying performance
RU2126249C1 (en) Pharmaceutical composition for oral administration for treatment of patients with pathology of gastroenteric tract upper regions
De Conno et al. Oral complications in patients with advanced cancer
AU1835201A (en) Treatment of fibromyalgia with Ubiquinone 10 and succinic acid
RU2261098C2 (en) Mirtazapine-containing orally decomposing composition
JP2001518481A (en) Serotonin-containing preparations for oral administration and methods of use
JPS6393710A (en) Slow release fluoride composition
JPH01261334A (en) Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof
JPH09301879A (en) Pharmaceutical composition
JPH07126163A (en) Controllably releasable pilocarpine transmitting system
Dekker et al. An international multi-clinic study comparing the therapeutic efficacy of colloidal bismuth subcitrate coated tablets with chewing tablets in the treatment of duodenal ulceration
US5216019A (en) Pain killer
US20070053930A1 (en) Combination therapy for treatment of high cholesterol
WO1994001108A1 (en) Controlled release pilocarpine delivery system
JP3937448B2 (en) H. Use of spiramycin for the treatment of gastrointestinal disorders caused by Pylori
RU2354378C1 (en) Combined anti-tuberculosis preparation
Westergren et al. Effective once-daily treatment of hypertension with low-dose, controlled-release metoprolol: pooled results from three randomized, double-blind, placebo-controlled studies

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070913

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070918

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080222

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20090605

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20090624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110218

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110412

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140422

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140422

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term